Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab induction and maintenance in relapsed/refractory Waldenström macroglobulinemia
2016-005053-20Phase 2Completed
- Sponsor
- Polish Myeloma Consortium
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in Waldenström macroglobulinemia (WM), sponsored by Polish Myeloma Consortium. Primary endpoint: Best Overall Response. Started Dec 2017; status: completed.
02
Drugs
obinutuzumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2016-005053-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005053-20.